Gene and Cell Therapies Expected to Offer New Treatment Paradigm in CNS Disorders; Market Expected to Increase at a CAGR of 45% During the Study…

LAS VEGAS, July 26, 2021 /PRNewswire/ -- DelveInsight's 'Gene and Cell Therapies Targeting CNS Disorders Market Insights and Market Forecast 2026' report offers a panoramic view of the current treatment practices, emerging cell and gene therapies to treat CNS disorders, market share of the individual therapies, current and forecasted Gene and Cell Therapies Targeting CNS Disorders market in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan) for the study period 20182026.

Some of the focal points extracted from the Gene and Cell Therapies Targeting CNS Disorders Marketreport:

Know more about the emerging therapy expected to penetrate the market significantly @ Gene and Cell Therapies Targeting CNS Disorders Market Insights, Pipeline Therapies, and Emerging Trends

The report is created to project true opportunities in the Gene and Cell Therapies Targeting CNS Disorders market landscape, to help clients gain a competitive advantage over competitors, and to plan strategic moves to yield maximum ROI.

CNS Disorders Burden

Central Nervous System (CNS) Disorders are one of the most prevailing and destructive disorders that are often poorly understood and have limited treatment options. It contributes to the highest disability-adjusted life years (DALYs) and is the second leading cause of death in the United States. The past three decades witnessed a substantial rise in the diagnosis of neurological disorders, which are further expected to increase in coming years.

CNS diseases can arise as a concomitant condition due to complicated disorders like ischemic, hemorrhagic, neurodegenerative, inflammatory, developmental disorders, damage from an infection, a degenerative condition, stroke, a brain tumor, or can be inherited.

Burden of death and disability because of CNS disorders is a major cause of concern primarily driven by global population growth and aging; a lack of understanding of the pathophysiology of the CNS disorders, underlying risk factors that may lead to CNS disorders and so on.

Unmet Needs in the Market

At present, there is no curative option available in the healthcare and pharmaceutical market, and the drug development of curative and effective therapies is hindered by several challenges.

First and foremost, the mechanisms of CNS diseases are quite difficult to understand because of a lack of complete understanding of the brain functioning, which inarguably is the most complicated organ in the human body.

Secondly, the major barrier is imposed by a dearth of standard targets for the treatment of CNS disorders. Target or biomarker identification, in this case, appears quite challenging owing to apparent defects in synaptic communication and functional connectivity and a lack of knowledge on genetic causes that are behind the CNS disorders. Studies of the pathophysiology of CNS disorders have failed to generate any fruitful results owing to the heterogeneity of the diseases.

As per the estimates, more than 98% of the smaller molecular drugs and almost 100% large molecular therapeutics fail to offer effective care in CNS Disorders owing to their inability to cross BBB.

Want to know more? Get comprehensive insights @Gene and Cell Therapies Targeting CNS Disorders

Get customized solutions and expand your business in the Gene and cell therapy market in the emerging markets through Delveinsight's Pharma market consulting and customized solutions

Gene and Cell Therapy Market

Just like any sector, Gene and cell therapy marketalso went into the stage of quiescent with the stoppage of trials and shifting of focus towards COVID-19 therapeutics and prophylactics development, however, the R&D restored its pace, and the year 2020 witnessed significant developments and approvals with the majority in oncology.

Gene and Cell Therapies Targeting CNS Disorders Market Analysis

At present, numerous Cell and Gene Therapies (CGTs) are under different stages of clinical development indicated for most devastating CNS disorders such as Spinal injury, Alzheimer's disease (AD), Parkinson's disease(PD), Huntington's disease (HD), Spinal cord injury (SCI), Amyotrophic lateral sclerosis (ALS), Multiple sclerosis (MS), Spinal muscular atrophy (SMA), and others.

The major players such as BrainStorm Cell Therapeutics, Helixmith, Corestem, Q therapeutics, and others are investigating their therapies in Phase II and III stages of development for different CNS Disorders.

Drop by @ Gene and Cell Therapies Targeting CNS Disorders to learn more about the recent strides in R&D in CGTs being developed to treat CNS Disorders

Gene and Cell Therapies Targeting CNS Disorders Pipeline Therapies

Therapy

Company

Indication

Phase

NurOwn

BrainStorm Cell Therapeutics

Amyotrophic lateral sclerosis

III

NurOwn

BrainStorm Cell Therapeutics

Multiple

Sclerosis/ Chronic Progressive

II

Engensis

Helixmith

Amyotrophic Lateral Sclerosis

II

HYNR-CS inj

Corestem

Amyotrophic Lateral Sclerosis

I/II

Q-Cells

Q Therapeutics

Amyotrophic Lateral Sclerosis

I/II

VM202

Helixmith

Amyotrophic Lateral Sclerosis

I/II

RAPA-501 Autologous T cells

Rapa Therapeutics

Amyotrophic Lateral Sclerosis

I/II

Neuro-Cells

Neuroplast

Spinal Chord Injuries

I & II/III

Umbilical Cord Blood Mononuclear Cell

StemCyte

Spinal Chord Injuries

II

itMSCs

Stemedica Cell Technologies

Alzheimer's Disease

II

AAV-hTERT

Libella Gene Therapeutics

Alzheimer's Disease

I

ST-501

Sangamo Therapeutics

Alzheimer's Disease

Pre-clinical

VY-AADC

Voyager Therapeutics

Parkinson's Disease.

I & II

Lomecel-B

Longeveron

Alzheimer's Disease

I

AXO Lenti PD

Axovent

Parkinson's Disease

II

PR001

Prevail Therapeutics

PD-GBA

I/II

Neural Stem

Cell-Derived Neurons

NeuroGeneration

Parkinson's Disease

II/III

AAV2-GDNF

AskBio

Parkinson's Disease

I

See the original post:

Gene and Cell Therapies Expected to Offer New Treatment Paradigm in CNS Disorders; Market Expected to Increase at a CAGR of 45% During the Study...